Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Celltrion Wins Bid to Supply Remsima®, Infliximab Biosimilar, and Herzuma®, Trastuzumab Biosimilar, in Peru

May 2, 2024

On 2 May 2024, Celltrion announced that it has won a 12 month tender to supply Remsima®, biosimilar to Janssen’s Remicade® (infliximab) and Herzuma®, biosimilar to Roche’s Herceptin® (trastuzumab), in Peru.  Celltrion expects to capture 86% of Peru’s infliximab market and 50% of Peru’s trastuzumab market.  Remicade® will be supplied from the end of May while Herzuma® will be supplied from July 2024.

This follows Celltrion’s recent tender successes regarding Remsima SC® in Denmark(April 2024), Norway (February 2024), and Sicily (January 2024).  In February 2024, Celltrion also secured a series of tenders in Peru to supply Herzuma® (trastuzumab biosimilar), Truxima® (rituximab biosimilar) and Yuflyma® (adalimumab biosimilar).   These contracts effectively secured more than 50% of the Peruvian rituximab and trastuzumab markets, and an estimated 20% of the Peruvian adalimumab market.